Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
By admin at 2006-11-22 11:03
 

* Segel GB, * Lichtman MA. Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.

 

We have reviewed the world's literature that addresses familial leukemiaterm, lymphomaterm, and myeloma. We have catalogued the phenotypic abnormalities associated with an increased risk of developing a hematological malignancy. These syndromes, such as Fanconi anemia or familial platelet syndrome, have been well characterized and in many cases the gene responsible for the predisposition has been defined. We have focused, however, on reports of a familial incidence of hematological malignancy in which no prior predisposing syndrome was reported. In this circumstance, so-called pure familial leukemia, lymphoma, or myeloma, the intergenerational incidence of disease occurred in ostensibly healthy persons. These families have been grouped into sets in which (a) anticipation, (b) immune abnormalities, (c) linkage to HLA phenotypes, (d) linkage to chromosome abnormalities, or (e) gene abnormalities have been reported.

read more | 3089 reads

New Survival Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer
By admin at 2006-11-18 06:28
 
<p>Â*Â*Â*Â* <strong>First </strong>Patient Enrolled in Phase III International Randomised, Double-Blind, Placebo-Controlled Study of <strong>Vandetanib </strong>for Non-Small Cell Lung Cancer (NSCLC) </p><p>&nbsp;</p><p>After Failure of EGFR TKI Therapy AstraZeneca today announced the start of enrolment into a <strong>new </strong>Phase III study of the novel once-daily oral anti-cancer drug vandetanib (ZACTIMA(TM), ZD6474) as third/fourth line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following EGFR TKI therapy. </p><p>&nbsp;</p>
read more | 3054 reads

FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
By admin at 2006-11-18 05:44
 
Only Targeted Biologic Therapy Approved for Use in Adjuvant and Metastatic HER2-positive Breast Cancer -

SOUTH SAN FRANCISCO, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE-DNA) announced today that the U.S. Food and Drug Administration (FDA) approved Herceptin(R) (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.
read more | 2936 reads

CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
By admin at 2006-11-18 05:26
 

BRANFORD, Conn., Nov. 16 /PRNewswire-FirstCall/ -- CuraGen Corporation (NASDAQ:CRGN)
and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of Myelodysplastic Syndromes (MDS). This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for PXD101.

read more | 2021 reads

Targeting Leukemic Stem Cells by BCL-2 Inhibition
By admin at 2006-11-18 04:40
 

HOUSTON, Nov. 17 /PRNewswire/ -- Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemiaterm (AML) blastterm, progenitor and even stem cells that are often resistant to standard chemotherapyterm treatment.

The drug was powerful in its own right, the researchers say, but they found that some AML cells were themselves resistant to ABT-737, so they added another drug that knocked out this secondary resistance. Together, these agents may provide a powerful therapy against AML, and could form the basis of a new way to treat the cancer, say the scientists, whose study was published in the November 14 issue of the journal, Cancer Cell.

read more | 2274 reads

$20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
By admin at 2006-11-15 02:28
 

STANFORD, Calif.---The Stanford University School of Medicine has received a $20 million gift to establish a new world-class research enterprise to study cancer stem cells, which are believed to be at the heart of most cancers.

 

The New York-based Virginia and D.K. Ludwig Fund announced Nov. 14 that the money was part of a $120 million commitment—one of the largest gifts ever by a private foundation for cancer research—for Stanford and five other academic centers nationwide. At Stanford, the funding will be used to launch the Ludwig Center for Cancer Stem Cell Research and Medicine, and build upon the distinguished discoveries that Stanford researchers have made in this field. The goal of the center is to identify and better understand the role of these elusive cells in common cancers and then use this knowledge to develop more effective treatments. Most of the initial grant will be used to create a permanent endowment for the Ludwig Center. “These funds will enable us not only to advance our initiatives on human cancer stem cells, but also to strengthen other unique aspects of Stanford’s cancer activities—from genomics to clinical care,” said Irving Weissman, MD, who in 2005 assumed a professorship at Stanford endowed by the fund—the Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research. (Another Ludwig chair was endowed in 1998 and is held by Lucy Shapiro, PhD.) Weissman, who first identified blood-forming stem cells in humans and mice, will direct the new enterprise. Michael Clarke, MD, professor of medicine (oncology) and the first scientist to identify cancer stem cells in breast cancer, will serve as its deputy director. In addition to promoting cancer stem cell research at Stanford, Weissman said he hoped Stanford researchers would, through the Ludwig network, interact with other groups that are complementary to their work. For instance, Weissman noted that scientists with the Ludwig Center at Memorial Sloan-Kettering are focused on the immunology of cancer; Stanford researchers will collaborate with them in examining the immune responses to cancer stem cells, he said.

read more | 1827 reads

Australian Discovery Could Lead To New Leukemia Treatments
By admin at 2006-11-14 22:43
 

The protein-- Stat5 -- was investigated at a laboratory at Deakin University's Melbourne Campus at Burwood, as part of a multicentre international collaboration. leukemiaterm is a cancer caused by a proliferation of white blood cells.

 

To understand and help prevent the disease, the Deakin researchers are looking for the responsible genes. Head of the Deakin team, Associate Professor Alister Ward, said the discovery of how the protein acts provides a breakthrough in understanding the onset of leukemia. "We have found that Stat5 is responsible for making white blood cells overgrow in a particular disease setting that often precedes leukemia," Associate Professor Ward explained. "On top of this, we have also found that Stat5, when activated, is sufficient on its own to cause white blood cells to overgrow inside a whole organism. "Together, these findings identify Stat5 as a major player in the process of leukemia progression and is therefore a worthwhile target for intervention." Associate Professor Ward said the next step in this research was to utilise the model systems established to develop new therapeutics.

2009 reads

Nanoparticle-arsenic combination makes for more potent anticancer agent
By admin at 2006-11-14 07:16
 
Thomas O’Halloran, Ph.D., and colleagues at Northwestern University’s Nanomaterials for Cancer Diagnostics and Therapeutics Center for Cancer Nanotechnology Excellence (CCNE) report on a new method of incorporating arsenic trioxide into lipid particles in order to aid in entrance to tumor cells. What makes their method unique is that by prefilling the lipid spheres with metals, the arsenic trioxide binds tighter and releases acetic acid, which pushes the equilibrium or arsenic towards entering the cell, sort of a positive feedback mechanism.

[url]http://www.nanowerk.com/news/newsid=1017.php[/url]
read more | 2119 reads

Acute Myelogenous Leukemia
By admin at 2006-11-09 01:35
 

A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a majority of patients had antecedent myelodysplastic syndrome. Complete remission was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%. The median duration of CR was 7.3 months and the median survival of complete responders was 18 months. Adverse karyotype, age >/=75, and poor performance status correlated negatively with survival. Early death in the absence of progressive disease was rare, and drug-related non-hematologic serious adverse events were observed in 74 patients (47%). Inhibition of farnesylation of the surrogate protein HDJ-2 occurred in the large majority of marrow samples tested. Baseline levels of phosphorylated mitogen-activated protein kinase and AKT did not correlate with clinical response. Tipifarnib is active and well tolerated in older adults with poor-risk AML, and may impart a survival advantage in those patients who experience a clinical response.

read more | 3116 reads

 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 06:29 AM.